AMEX:XXII

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has 22nd Century Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: XXII's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

0.7%

XXII

0.8%

US Tobacco

2.1%

US Market


1 Year Return

43.8%

XXII

-18.3%

US Tobacco

19.8%

US Market

Return vs Industry: XXII exceeded the US Tobacco industry which returned -18.3% over the past year.

Return vs Market: XXII exceeded the US Market which returned 19.7% over the past year.


Shareholder returns

XXIIIndustryMarket
7 Day0.7%0.8%2.1%
30 Day95.5%8.7%8.1%
90 Day137.8%-7.5%6.0%
1 Year43.8%43.8%-11.1%-18.3%22.5%19.8%
3 Year-35.2%-35.2%-26.9%-39.7%46.5%36.8%
5 Year13.5%13.5%-7.3%-29.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is 22nd Century Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 22nd Century Group undervalued compared to its fair value and its price relative to the market?

4.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XXII is unprofitable, so we can't compare its PE Ratio to the XX Tobacco industry average.

PE vs Market: XXII is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XXII's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XXII is overvalued based on its PB Ratio (4.2x) compared to the US Tobacco industry average (2.6x).


Next Steps

Future Growth

How is 22nd Century Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-2.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XXII is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XXII is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XXII is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XXII's revenue is expected to decline over the next 3 years (-5.2% per year).

High Growth Revenue: XXII's revenue is forecast to decline over the next 3 years (-5.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XXII's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has 22nd Century Group performed over the past 5 years?

-18.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XXII is currently unprofitable.

Growing Profit Margin: XXII is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XXII is unprofitable, and losses have increased over the past 5 years at a rate of 18.8% per year.

Accelerating Growth: Unable to compare XXII's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XXII is unprofitable, making it difficult to compare its past year earnings growth to the Tobacco industry (-2.7%).


Return on Equity

High ROE: XXII has a negative Return on Equity (-38.98%), as it is currently unprofitable.


Next Steps

  • Explore strong past performing companies in the Food, Beverage & Tobacco industry.

Financial Health

How is 22nd Century Group's financial position?


Financial Position Analysis

Short Term Liabilities: XXII's short term assets ($33.1M) exceed its short term liabilities ($6.5M).

Long Term Liabilities: XXII's short term assets ($33.1M) exceed its long term liabilities ($819.0K).


Debt to Equity History and Analysis

Debt Level: XXII's debt to equity ratio (3.6%) is considered satisfactory.

Reducing Debt: XXII's debt to equity ratio has reduced from 7.8% to 3.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XXII has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XXII has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.2% each year.


Next Steps

Dividend

What is 22nd Century Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XXII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XXII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XXII's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XXII's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XXII's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Jim Mish (56 yo)

0.42

Tenure

Mr. James E. Mish, also known as Jim, serves as Chief Executive Officer at 22nd Century Group, Inc. since June 22, 2020. He has extensive global executive leadership experience in science-driven organizati...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Zercher
President & COO0.92yrUS$1.01m0.015%
$ 31.3k
John Brodfuehrer
CFO & Treasurer7.67yrsUS$484.12kno data
Henry Sicignano
Consultant1.33yrsUS$913.22kno data
James Mish
Chief Executive Officer0.42yrno data0.18%
$ 377.5k
John Franzino
VP of Administration & CFO0.42yrno datano data
Mei Kuo
Director of Communications & Investor Relations0.67yrno datano data
Steven Przybyla
General Counsel & Corporate Secretary0.33yrno datano data
James Morrison
Technical Advisor & Regulatory Affairs Consultant13.83yrsno datano data

0.8yrs

Average Tenure

56yo

Average Age

Experienced Management: XXII's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Nora Sullivan
Independent Chairman0.83yrUS$201.22k0.14%
$ 287.9k
Richard Sanders
Independent Director6.92yrsUS$201.22k0.070%
$ 146.5k
Clifford Fleet
Director1.25yrsUS$514.12k0.072%
$ 151.0k
Roger O'Brien
Independent Director0.83yrno datano data
Michael Koganov
Director0.17yrno datano data

0.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: XXII's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XXII insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.


Top Shareholders

Company Information

22nd Century Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 22nd Century Group, Inc.
  • Ticker: XXII
  • Exchange: AMEX
  • Founded: 1998
  • Industry: Tobacco
  • Sector: Food, Beverage & Tobacco
  • Market Cap: US$209.677m
  • Shares outstanding: 138.86m
  • Website: https://www.xxiicentury.com

Number of Employees


Location

  • 22nd Century Group, Inc.
  • 8560 Main Street
  • Suite 4
  • Williamsville
  • New York
  • 14221
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XXIIAMEX (NYSE MKT LLC)YesCommon StockUSUSDJan 2011
22NDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2011
0LHJLSE (London Stock Exchange)YesCommon StockGBUSDJan 2011

Biography

22nd Century Group, Inc., a plant biotechnology company, provides technology that allows to alter the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis pl...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 23:16
End of Day Share Price2020/11/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.